Rare Disease Research
Rare Disease Market Research and Patient Recruitment Services
Pharmaceutical companies, biotech firms, and CROs need insights that standard market research panels cannot provide. Rare disease populations are small, geographically dispersed, and medically complex. MedPanel is built specifically for this problem.
For more than 20 years, we have connected life science organizations with verified rare disease patients, caregivers, and treating physicians. We deliver evidence that moves clinical and commercial decisions forward — from early development through post-launch assessment.
Why Rare Disease Market Research Requires a Specialist
General market research providers are not designed for rare disease studies. The challenges are structural:
Patient populations for individual rare diseases often number in the thousands globally, not millions. Standard panels do not contain them.
Diagnosis verification is essential. Self-reported rare disease status without physician confirmation produces unreliable data.
Recruiting through advocacy organizations and physician networks — not consumer databases — is the only method that reaches verified participants at scale.
Regulatory sensitivity requires HIPAA, GDPR, and ISO-20252 compliance at every stage of recruitment and data handling.
MedPanel addresses each of these requirements through a purpose-built methodology that has supported hundreds of rare disease research engagements worldwide.
Our Rare Disease Research Capabilities
Patient & Caregiver Research
We recruit and verify rare disease patients and caregivers for qualitative interviews, quantitative surveys, focus groups, and longitudinal studies. Research topics include disease burden, treatment experience, quality of life, unmet needs, and patient journey mapping.
Populations include ultra-rare, pediatric, metabolic, neurological, hematological, and oncology conditions.
Healthcare Professional (HCP) Engagement
We engage treating specialists — including physicians who manage fewer than a handful of rare disease patients per year — through our verified physician network.
HCP research covers prescribing patterns, treatment decision-making, diagnostic pathways, and therapy perception. Physicians are identified by specialty, practice setting, and confirmed patient experience.
Quantitative & Qualitative Research Design
Our research team supports study design from protocol through delivery. Methods include structured web surveys, in-depth interviews (IDIs), online focus groups, patient diaries, and hybrid designs.
All instruments are developed with the target population in mind — including health literacy adaptations for complex rare disease populations.
Payer & Policy Research
For rare disease programs approaching market access, we recruit and survey payers, formulary decision makers, and health economists.
Studies assess coverage expectations, value-based evidence requirements, and policy considerations that influence rare disease therapy adoption.
Therapeutic Areas
MedPanel has active experience across a wide range of rare and ultra-rare conditions. Recent engagements include:
This is not an exhaustive list. If your target condition is not listed, contact us to discuss feasibility.
Who We Work With
Clients engaging MedPanel for rare disease market research include pharmaceutical and biotechnology companies (brand, medical affairs, and HEOR teams), contract research organizations (CROs), healthcare management consultancies, patient advocacy organizations, and academic medical centers. Studies span Phase II feasibility through post-launch real-world evidence.
Pharmaceutical & Biotechnology Companies
Brand, medical affairs, and HEOR teams.
Contract Research Organizations (CROs)
Recruitment partner for rare disease studies.
Healthcare Management Consultancies
Strategic insight engagements with end-client deliverables.
Patient Advocacy Organizations
Community-led research and patient voice initiatives.
Academic Medical Centers
Investigator-led and translational research projects.
Compliance and Data Standards
All rare disease market research conducted by MedPanel follows HIPAA, GDPR, and ISO-20252 protocols. Participant data is handled with the heightened care appropriate to small, identifiable rare disease communities. We do not aggregate rare disease patient data across clients or use participant information beyond the scope of the commissioned study.
HIPAA
Protected Health Information
GDPR
EU Data Protection
ISO-20252
Market Research Quality
Published Research
All rare disease market research conducted by MedPanel follows HIPAA, GDPR, and ISO-20252 protocols. Participant data is handled with the heightened care appropriate to small, identifiable rare disease communities. We do not aggregate rare disease patient data across clients or use participant information beyond the scope of the commissioned study.
Frequently Asked Questions
Rare disease studies require recruiting from a pool of patients that may number in the hundreds or low thousands globally. Standard consumer or physician panels do not contain these participants. Verification of diagnosis is critical because self-reporting is unreliable at this scale. MedPanel reaches verified participants through physician networks, advocacy organizations, and its own opt-in rare disease respondent community.
Yes. Many rare disease programs benefit from triangulating patient-reported experience with physician treatment patterns and clinical perspectives. MedPanel manages both tracks within a single engagement, ensuring methodological consistency across respondent types.
We support qualitative research (in-depth interviews, focus groups), quantitative surveys, patient journey studies, disease burden assessments, unmet needs analyses, message testing, and HEOR-adjacent patient experience studies. Study design is tailored to the condition and the specific clinical or commercial question.
Verification methods include physician referral and confirmation, review of medical documentation, and patient portal verification where applicable. The method used depends on the condition and study requirements. We do not include self-reported diagnosis alone for rare disease studies.
Yes. MedPanel supports global rare disease studies across North America, Europe, and other regions. All international recruitment follows applicable local regulatory requirements, including GDPR for European participants.